Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28191935 | 0.93 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| Piperazine SCHEMBL28191934 | 0.91 | CA2 (0.44) | CA2CA12CA1CA9CHKA | |
| SCHEMBL31011078 | 0.84 | — | — | |
| SCHEMBL30455653 | 0.81 | CA2 (0.45) | CA2CA12CA1CA9CHKA | |
| SCHEMBL2184936 | 0.80 | ATM (0.50) | POLBKMT2AGAA | |
| SCHEMBL7364504 | 0.80 | CA2 (0.41) | CA2CA12CA1CA9CHKA | |
| SCHEMBL7364501 | 0.80 | CA2 (0.41) | CA2CA12CA1CA9CHKA | |
| SCHEMBL3898267 | 0.79 | CA2 (0.43) | CA2CA12CA1CA9CHKA | |
| SCHEMBL9737097 | 0.79 | CA2 (0.39) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5315426 | 0.78 | ATM (0.48) | KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531655-A | N aromatic alkyl carbonyls piperazine and N aromatic alkyl carbonyl homopiperazine compounds and include their personal care composition | 荷兰联合利华有限公司 | 2018-01-02 | — | — | CN | claimed |
| EP-2076503-B1 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | claimed |
| EP-2346507-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-07-27 | — | — | EP | claimed |
| US-7973012-B2 | C-phenyl glycitol compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-07-05 | — | — | US | claimed |
| WO-2010026029-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | claimed |
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | claimed |
| EP-2076503-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-07-08 | — | — | EP | claimed |
| EP-1572686-B1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2009-04-15 | — | — | EP | claimed |
| WO-2007136116-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-29 | — | — | WO | claimed |
| WO-2006089871-A2 | DIPHENYLUREA DERIVATIVES USEFUL AS ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH A/S (DK) | 2006-08-31 | — | — | WO | claimed |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | claimed |
| EP-1572686-A1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | Novartis AG (CH) | 2005-09-14 | — | — | EP | claimed |
| EP-0876345-B1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-08-18 | — | — | EP | claimed |
| WO-2004052884-A1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | claimed |
| US-6008230-A | TREATING BONE DISEASES CAUSED BY ABNORMAL BONE METABOLISM IN HUMAN BEING OR ANIMALS AS THE INHIBITORS OF BONE RESORPTION OR THE INHIBITORS OF BONE METASTASIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | claimed |
| EP-0937048-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1999-08-25 | — | — | EP | claimed |
| EP-0876345-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-11 | — | — | EP | claimed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | claimed |
| WO-1997014681-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-24 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| CN-109553641-B | Novel pincer-like metal complex and application thereof | 中国科学院上海有机化学研究所 | 2023-05-12 | — | — | CN | disclosed |
| EP-3915986-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Voronoi Inc. (KR) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020185044-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 보로노이 | 2020-09-17 | — | — | WO | disclosed |
| CN-109553641-A | Novel pincer metal complex and its application | 中国科学院上海有机化学研究所 | 2019-04-02 | — | — | CN | disclosed |
| CN-107531655-A | N aromatic alkyl carbonyls piperazine and N aromatic alkyl carbonyl homopiperazine compounds and include their personal care composition | 荷兰联合利华有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107531655-A | N aromatic alkyl carbonyls piperazine and N aromatic alkyl carbonyl homopiperazine compounds and include their personal care composition | 荷兰联合利华有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107531655-A | N aromatic alkyl carbonyls piperazine and N aromatic alkyl carbonyl homopiperazine compounds and include their personal care composition | 荷兰联合利华有限公司 | 2018-01-02 | — | — | CN | disclosed |
| EP-2076503-B1 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| CN-101321529-B | Diaryl aether derivant as antineoplastic agent | OTSUKA PHARMA CO LTD | 2012-09-05 | — | — | CN | disclosed |
| EP-2346507-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7973012-B2 | C-phenyl glycitol compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-07-05 | — | — | US | disclosed |
| WO-2010026029-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2076503-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-1572686-B1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7504537-B2 | Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| EP-2004652-A1 | 3-UNSUBSTITUTED N-(ARYL- OR HETEROARVL)-PYRAZOLORI Ý1,5-A¨PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| EP-2004653-A1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-a]PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007136116-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007113000-A1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-a]PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007112998-A1 | 3-UNSUBSTITUTED N-(ARYL- OR HETEROARVL)-PYRAZOLORI [1,5-A]PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2006089871-A2 | DIPHENYLUREA DERIVATIVES USEFUL AS ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH A/S (DK) | 2006-08-31 | — | — | WO | disclosed |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | disclosed |
| US-20050282905-A1 | Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1572686-A1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | Novartis AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| EP-1466899-A1 | HYDROXAMIC ACID DERIVATIVE AND MMP INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-0876345-B1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004052884-A1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | disclosed |
| US-20040006142-A1 | Ocular tension depressor | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1280523-A2 | USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF HIGH OCULAR TENSION AND GLAUCOMA | Sucampo AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| US-6486155-B1 | Method of inhibiting neoplastic cells with isoquinoline derivatives | CELL PATHWAYS INC | 2002-11-26 | — | — | US | disclosed |
| WO-2001082913-A2 | USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF HIGH OCULAR TENSION AND GLAUCOMA | SUCAMPO AG (CH) | 2001-11-08 | — | — | WO | disclosed |
| US-6020339-A | Aryl furan derivatives as PDE IV inhibitors | MERCK & CO., INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-6008228-A | COMPRISING A MIXTURE OF CARRIER MONOGLYCERIDES OF MEDIUM CHAIN-FATTY ACIDS | HOFFMAN-LA ROCHE INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-6008230-A | TREATING BONE DISEASES CAUSED BY ABNORMAL BONE METABOLISM IN HUMAN BEING OR ANIMALS AS THE INHIBITORS OF BONE RESORPTION OR THE INHIBITORS OF BONE METASTASIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| EP-0876345-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5753619-A | CYCLIC HEPTAPEPTIDES FOR CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INSUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0831826-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997014681-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-24 | — | — | WO | disclosed |
| WO-1996039142-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-12 | — | — | WO | disclosed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0669334-A1 | TRICYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-08-30 | — | — | EP | disclosed |
| US-5409927-A | Inhibition of hiv aspartate protease | CIBA-GEIGY CORPORATION (US) | 1995-04-25 | — | — | US | disclosed |
| US-4297358-A | AS ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1981-10-27 | — | — | US | disclosed |
| US-4221806-A | ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1980-09-09 | — | — | US | disclosed |
| US-4205082-A | ANTI-ALLERGIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-05-27 | — | — | US | disclosed |
| US-4205082-A | ANTI-ALLERGIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | SLC5A1, SLC5A2, SLC2A1 | CA2 180/4885CA12 425/4885CA1 885/4885 |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | TTK, TTBK1, TTBK2 | CA2 1093/4885CA12 3872/4885CA1 3141/4885 |
| US-20040006142-A1 | Ocular tension depressor | TPH2, TPH1, ALDH1A2 | CA2 154/4885CA12 4008/4885CA1 3647/4885 |
| US-20050282905-A1 | Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient | MMP13, MMP3, MMP2 | CA2 74/4885CA12 303/4885CA1 103/4885 |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | AADAC, AADAT, NAAA | CA2 305/4885CA12 357/4885CA1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.